title: Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
abstract: BACKGROUND
  This is a phase 2 study of chemotherapy-naive patients, 70 years of age or older, with nonsmall-cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS).
  
  
  METHODS
  Eligible patients were treated with docetaxel 75 mg/m(2) every 3 weeks and gefitinib 250 mg orally, daily. Docetaxel and gefitinib were given for 2 cycles beyond maximal response. Gefitinib was continued until disease progression. Comorbidities and activities of daily living were assessed (IADL).
  
  
  RESULTS
  Forty-four patients initiated therapy between March 2003 and May 2005. Seventeen patients (40%; 95% confidence interval [CI], 26%-57%) had a partial response and 48% had stable disease. The median PFS was 6.9 months (95% CI, 3.95-7.8 months). Median survival time was 9.6 months (95% CI, 4.6-16.3 months). On univariate analyses, sex, Eastern Cooperative Oncology Group Performance Status (ECOG PS), and Charlson comorbidities index (CCI) score were predictors of improved survival. On multivariate analyses female sex was a statistically significant predictor of survival. The median survivals were 22.8 months in women and 4.8 months in men. This regimen was well tolerated, with the most common adverse events being hyperglycemia, fatigue, and lymphopenia.
  
  
  CONCLUSIONS
  Docetaxel combined with gefitinib is active and well tolerated in patients with advanced NSCLC who are 70 years of age and older. This paradigm of treatment merits further investigation as a first-line treatment strategy. Female sex-specific confirmatory clinical trials with this regimen may be warranted.
authors.affiliation: Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. george.simon@moffitt.org
authors.forename: George R
authors.initials: GR
authors.lastname: Simon
authors.forename: Martine
authors.initials: M
authors.lastname: Extermann
authors.forename: Alberto
authors.initials: A
authors.lastname: Chiappori
authors.forename: Charles C
authors.initials: CC
authors.lastname: Williams
authors.forename: Mubeena
authors.initials: M
authors.lastname: Begum
authors.forename: Rachna
authors.initials: R
authors.lastname: Kapoor
authors.forename: Eric B
authors.initials: EB
authors.lastname: Haura
authors.forename: Roohi
authors.initials: R
authors.lastname: Ismail-Khan
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Schell
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Antonia
authors.forename: Gerold
authors.initials: G
authors.lastname: Bepler
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D015897:Comorbidity; D000077143:Docetaxel; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D008297:Male; D009154:Mutation; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; D066246:ErbB Receptors; D000077156:Gefitinib